The purpose of the study is to find out whether PIPE-791 can preserve breathing ability better than the placebo. Participants will take the study medication or placebo every day for about six months, with regular visits to check health, report any side effects, and undergo simple breathing tests. One of the key breathing tests measures forced vital capacity (FVC), which is the amount of air a person can push out of the lungs after taking a deep breath; this helps doctors see how the lungs are working. At selected visits, a special detailed X‑ray scan called HRCT will be used to look at the amount of scarring in the lungs. The study follows participants for the full treatment period to monitor safety and how well the drug works.

After successful angioplasty, eligible individuals are divided into two groups: one continues taking riociguat and the other stops the medication. Both groups are followed for at least twelve months, with regular clinic visits to monitor health status. Simple tests include a walking test that measures how far a person can walk in six minutes (6‑minute walk distance) and questionnaires that assess daily functioning and quality of life, such as the EQ-5D-5L and disease‑specific EmPHasis‑10. Blood tests for a heart‑stress marker (NT-proBNP) and routine checks of heart function are also performed.

During the follow‑up period, any serious events such as death, hospitalization because of worsening lung pressure, right heart failure, need for a lung transplant, use of intravenous diuretics or inotropic support, or requirement of medication called prostanoids are recorded. The study aims to provide information on whether stopping riociguat after a successful procedure is safe or if continuing the medication offers better protection against these serious outcomes.

The research involves testing Orforglipron against a placebo in a carefully controlled study. Participants will take the medication or placebo as capsules once daily. The study will monitor changes in blood pressure, particularly focusing on measuring systolic blood pressure (the top number in a blood pressure reading) over a period of 36 weeks.

The study is designed as two separate but related trials under one master protocol. Both trials will look at how well Orforglipron works in controlling blood pressure in people who are overweight or have obesity. Throughout the study period, which may last up to 60 months, participants will have their blood pressure and other health measurements regularly monitored.

The purpose of the study is to determine whether adding the drug to the usual treatment, called standard of care, lowers the risk of returning to the hospital, visiting the ED, or dying after the flare‑up. After discharge, participants are randomly assigned to one of the two groups and receive injections at regular intervals while researchers check in with them through clinic visits and phone calls over several months.

Researchers will track how often participants experience another worsening of symptoms, known as an exacerbation, and will record any unplanned hospital readmissions, urgent care visits, or deaths. They will also ask participants to complete simple questionnaires that measure how the lung disease affects daily life and symptom severity. Any side effects or health problems that appear during the study will be recorded and evaluated.

The purpose of the research is to compare how a protein called TSLP is produced in airway cells after they are exposed to a laboratory substance that mimics a virus, known as poly(I:C). Participants will have samples taken from their nose and lungs at the start of the study, receive the study medication, and then provide additional samples at later visits. The collected cells are placed in a lab where they are exposed to the viral mimic, and researchers measure changes in the amount of TSLP protein and its genetic instructions (mRNA). The study also looks at other cells involved in allergy and inflammation, such as eosinophils (a type of white blood cell) and mast cells (cells that release chemicals during allergic reactions), to see how they respond over time.